GenPhar's main thrust, according to Schmaljohn, was the «technology edge» it brought to
virus vector development - particularly work on a non-replicating adenovirus that could express multiple proteins.
Not exact matches
They supported a range of studies, from work on gene therapy tools (including adenovirus and rous sarcoma
virus vectors) to
development of a new vaccine for the deadly Marburg
virus.
The
vector is a self - inactivating lentivirus — a member of a family of
viruses that can insert genes into mammalian cells and drive expression of those genes — that has been engineered to avoid triggering the
development of leukemia, a complication seen in previous gene therapy trials for immunodeficiency syndromes, including WAS.